Pharmacological therapies to minimise platelet transfusion

Transfusion Science

Volumn 22, Issue 3, 2000, Pages 149-153

  Norfolk, D R ^a   Seghatchian, J ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

BLEEDING; BLEEDING TENDENCY; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; DISEASE TRANSMISSION; FLUSHING; HUMAN; LIVER TRANSPLANTATION; PROSTATECTOMY; SURGERY; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOSIS;

ANTIFIBRINOLYTIC AGENTS; CARDIOPULMONARY BYPASS; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; GREAT BRITAIN; HEMORRHAGE; HUMANS; PLATELET TRANSFUSION; VASOPRESSINS; VON WILLEBRAND FACTOR;

EID: 0347939775     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(00)00040-0     Document Type: Conference Paper

References (47)

1. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts. New Engl J Med 1999;340:438-47.
2. Turner ML, Ironside JW. New-variant Creutzfeldt-Jacob disease: the risk of transmission by blood transfusion. Blood Rev 1998;12:255-68.
3. Serious Hazards of Transfusion (SHOT). Annual report 1997/98. Royal College of Pathologists, 1999.
4. Blachman MA, Ali AM, Richardson HL. Bacterial contamination of cellular blood components. Vox Sanguinis 1994;67:25-34.
5. Prowse CV. Alternatives to standard blood transfusion: availability and promise. Transfus Med 1999;9:287-99.
6. Harker LA. Bleeding after cardiopulmonary bypass. New Engl J Med 1986;314:1446-7.
7. McKenna R, Bachman F, Whittaker B, Gilson JR, Weinberg Jr. M. The hemostatic mechanisms after open-heart surgery. II Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70:298-308.
8. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiol 1991;75:388-93.
9. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesions formation. Am J Cardiol 1995;75(Suppl B):B12-7.
10. Royston D. High-dose aprotinin therapy: a review of the first five years experience. J Cardiothorac Anesthes 1992;6:76-100.
11. Norfolk DR, Ancliffe, PJ, Contreras M, Hunt BJ, Machin SJ, Murphy WG, Williamson LM. Consensus Conference on platelet transfusion (Synopsis of background papers), Royal College of Physicians of Edinburgh, 1997 27-28 November. Brit J Haematol 1998;101:609-17.
12. Simon TL, Akl BF, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Annals of Thorac Surg 1984;37:359-64.
13. Ogston D. Anti-fibrinolytic drugs. Chemistry, pharmacology and clinical usage. New York: Wiley, 1984:1-180.
14. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991;38:113-9.
15. Karski JM, Teasdale SJ, Norman PH, Carroll JA, Weisel RD, Glynn MFX. Prevention of post-bypass bleeding with tranexamic acid and ε-aminocaproic acid. J Cardiothorac Vasc Anest 1993;7:431-5.
16. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic ε-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study. J Thorac Cardiovasc Surg 1994;108:99-108.
17. Laupacis A. Fergusson D for the International study group of perioperative transfusion (ISPOT) investigators. Drugs to minimise perioperative blood loss in cardiac surgery - metaanalysis using perioperative blood transfusions as the outcome. Anesth Analg 1997;85:1258-67.
18. Munoz JJ, Birkmeyer NJO, O'Connor GT, Dacey LJ. Is ε-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A mata-analysis. Circulation 1999;99:81-9.
19. Horrow JC, van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiol 1995;82:383-92.
20. Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation pattern, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs ε-aminocaproic acid. J Cardiovasc Surg 1996;37:401-7.
21. Sharifi R, Lee M, Ray P, Millner SW, Dupont PF. Safety and efficacy of intravesical aminocaproic acid for bleeding after transurethral resection of prostate. Urology 1986;27:214-9.
22. Smith RB, Riach P, Kaufman JJ. ε-Aminocaproic acid and the control of post-prostatectomy bleeding: a prospective double-blind study. J Urol 1984;131:1093-5.
23. Kang Y, Lewis JH, Navalgund A, Russell MW, Bontempo FA, Niren LS, Starzl TE. ε-Aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiol 1987;66:766-73.
24. Boylan JF, Klincke JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiol 1996;85:1043-8.
25. Hiippala S, Strid L, Wennerstrand M, et al. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Brit J Anaesthesiol 1995;74:534-7.
26. Blombäck M, Johansson G, Johnsson H, Swedenborg J, Wabo E. Surgery in patients with von Willebrand's disease. Brit J Surg 1989;76:398-400.
27. Williamson R, Eggleston DJ. DDAVP and ε-ACA used for minor oral surgery in von Willebrand disease. Austral Dental J 1988;33:32-6.
28. Avvisati G, Wouter ten Cate J, Buller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989;2:122-4.
29. Sindet-Pedersen S, Ramstrom G, Bernvil S, Blombäck M. Hemostatic effect of tranexamic mouthwashes in anti-coagulant patients undergoing oral surgery. New Engl J Med 1989;320:840-3.
30. Wymenga LF, van der Boon WJ. Obstruction of the renal pelvis due to an insoluble blood clot after ε-aminocaproic acid therapy: resolution with intraureteral streptokinase instillations. J Urol 1998;159:490-2.
31. Sonntag VKH, Stein BM. Arteriopathic complications during treatment of subarachnoid haemorrhage with ε-aminocaproic acid. J Neurosurg 1974;40:480-5.
32. Rydin E, Lundberg PO. Tranexamic acid and intracranial thrombosis. Lancet 1976;2:49.
33. Chabbat J, Porte T, Tellier M, Steinbuch M. Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex. Thromb Res 1993;71:205-15.
34. Dietrich W, Spannagl M, Jochuml M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiol 1990;73:1119-26.
35. Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anti-coagulant action of aprotinin? J Cardiovasc Pharmacol 1996;27(Suppl 1):550-557.
36. Tice DA, Worth MH, Clauss RH, Reed GH. The inhibition by Trasylol of fibrinolytic activity associated with cardiovascular operations. Surg Gynaecol Obstet 1964;119:71-4.
37. Fergusson D, van Walraven C, Coyle D, Laupacis A. Economic evaluation of technologies to minimize perioperative transfusion. A systematic review of published studies. Transfus Med Rev 1999;13:106-17.
38. Klein M, Keith PR, Dauben H-P, et al. Aprotinin counterbalances an increased risk of perioperative hemorrhage in CABG patients pre-treated with aspirin. Eur J Cardiothorac Surg 1998;14:360-6.
39. Neuhaus P, Bechstein WO, Lefebre B, Blumhardt G, Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1989;2:924-5.
40. Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wylie G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg 1995;80:343-8.
41. Levy JH, Pifarre R, Horrow JC, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing coronary artery bypass grafting. Circulation 1995;92:2236-44.
42. Dietrich W. Incidence of hypersensitivity reactions. Ann Thorac Surg 1998;65(Suppl):560-74.
43. Manucci PM. DDAVP: twenty years after. Thromb Haemostas 1997;78:958.
44. Hunt BJ. Desmopressin and bleeding during invasive surgery. Eur J Anaesthesiol 1997;14(Suppl 14):2-49.
45. Erberst ME, Berkowitz LR. Hemostasis in renal disease: pathophysiology and management. Am J Med 1994;96:168-79.
46. Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989;2:675-6.
47. Triulzi DJ, Gilmore GD, Ness PM, Baumgartner WA, Schultheis A. Efficacy of autologous fresh whole blood or platelet-rich plasma in adult cardiac surgery. Transfusion 1995:35:627-34.